联系方式
个人简介
1980-1985年：佳木斯医学院，医学学士
1987-1990年：哈尔滨医科大学，医学硕士
1994-1997年：哈尔滨医科大学，遗传学博士
1985-1987年：佳木斯医学院，微生物与免疫教研室，助教
1990-1994年：哈尔滨医科大学，生物学教研室，讲师
1997-1999年：哈尔滨医科大学，预防医学博士后流动站，博士后
1999-2004年：哈尔滨医科大学，遗传学研究室，教授
2001-2003年：哈佛大学医学院，分子病理学实验室，访问学者
2004年-至今：哈尔滨工业大学，生命科学与技术学院，教授
Personal Profile
1980 - 1985 Jiamusi Medical College, Bachelor of Medicine
1987 - 1990 Harbin Medical University, Master of Medicine
1994 - 1997 Harbin Medical University, Doctor of Genetics
1985 - 1987 Department of Microbiology and Immunology, Jiamusi Medical College, Teaching assistant
1990 - 1994 Harbin Medical University, Department of Biology, Lecturer
1997 - 1999 Harbin Medical University, Postdoctoral research station of Preventive Medicine
1999 - 2004 Genetics Laboratory, Harbin Medical University, Professor
2001 - 2003 Harvard Medical School, Molecular Pathology Laboratory, Visiting Scholar
2004 - present Harbin Institute of Technology, School of Life Science and Technology, Professor
研究方向和领域
肿瘤细胞生物学
Tumor Cell Biology
肿瘤代谢组学
Tumor Metabolomics
肿瘤糖生物学
Tumor Glycobiology
主要研究方向
肿瘤相关基因表达与功能研究
Study on the expression and function of tumor related genes
肿瘤分子标志物
Tumor molecular markers
分子诊断
Molecular diagnosis
研究内容
主要开展肿瘤细胞生物学、重大疾病分子诊断、癌症代谢组和糖组学研究，实现生物医学技术转化。
1. 发现MARVELD1的多功能特征：高度保守，影响细胞运动迁移能力，参与个体多器官分化发育，影响内胚层上皮细胞的自稳状态，作为候选抑癌基因影响细胞表面的超微结构，抑制肿瘤细胞的迁移运动，并调控DNA损伤与修复功能。
2. 开展癌症代谢重编程研究：研究肝癌、胰腺癌和结肠癌的血清、组织和细胞中小分子代谢物特征，筛选高特异性的肿瘤标志物；构建原发性肝癌脂类代谢失衡的分子网络；揭示与胰腺癌密切相关的花生四烯酸代谢关键通路的作用机制。
3. 应对新型冠状病毒疫情，推进医工交叉，研发核酸检测一体化设备与试剂，快速实现技术转化。
Research Interests
Professor Li Yu's research focuses on tumor cell biology, molecular diagnosis of diseases, cancer metabolomics, glycomic and the transformation of biomedical technology.
1. Professor Li Yu's research team found that the multifunctional characteristics of MARVELD1 were highly conserved, affecting cell mobility and migration, participating in the differentiation and development of multiple organs, affecting the self-stable state of endodermal epithelial cells, affecting the ultrastructure of cell surface as a candidate tumor inhibitor gene, inhibiting the migration and movement of tumor cells, and regulating DNA damage and repair function.
2. The research team focuses on cancer metabolic reprogramming: To study the characteristics of small molecular metabolites in serum, tissues and cells of liver cancer, pancreatic cancer and colon cancer, and to screen high specific tumor markers; To construct the molecular network of lipid metabolism imbalance in primary liver cancer; To reveal the mechanism of the key pathway of arachidonic acid metabolism which is closely related to pancreatic cancer.
3. In response to the Novel coronavirus outbreak, we have promoted the integration of medical and industrial research and development, and developed integrated nucleic acid testing equipment and reagents, so as to achieve rapid technology transformation.
研究成果
近五年内承担或主持重要项目6项，其中包括：中国工程院防疫应急重大仪器研究项目、黑龙江省“头雁”计划、国家自然科学基金面上项目以及深圳市科创委学科布局项目、深圳市科创委技术攻关项目等。
主要代表性科研论文：
1. Xiaoqing Zhang, Peng Dou, Muhammad Luqman Akhtar, Fei Liu, Xibo Hu, Lijun Yang, Depeng Yang, Xiaohan Zhang, Yiqun Li, Shupei Qiao, Kai Li, Ran Tang, Chao Zhan, Yue Ma , Qixiang Cheng, Yan Bai, Fang Han, Huan Nie*, Yu Li*.NEU4 inhibits motility of HCC cells by cleaving sialic acids on CD44.Oncogene, doi: 10.1038/s41388-021-01955-7. 2021.
2. Depeng Yang, Lijun Yang, Jialing Cai, XiboHu, Huaxin Li, Xiaoqing Zhang, Xiaohan Zhang, Xinghe Chen, Haiyang Dong, Huan Nie*, Yu Li*. A sweet spot for macrophages: Focusing on polarization. Pharmacol Res. 167:105576. doi: 10.1016/j.phrs.2021.105576. 2021.
3. Chunbo Wang, Depeng Yang, Xiaoqing Zhang, Xiaohan Zhang, Lijun Yang, Pingping Wang, Wenyang Zhou, Huaxin Li, Yiqun Li, Huan Nie, Yu Li*. Association of PTEN Gene SNPs rs2299939 With PFS in Patients With Small Cell Lung Cancer Treated With Early Radiotherapy.Front Genet. 23; 11:298. doi: 10.3389/fgene.00298. eCollection 2020.
4. Xiaohan Zhang, Xiuyun Shi, Xin Lu, Yiqun Li, Chao Zhan, Muhammad Luqman Akhtar, Lijun Yang, Yunfan Bai, Jianxiang Zhao, Yu Wang, Yuanfei Yao, Yu Li*, and Huan Nie. Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples. J Cancer. 11(16): 4641- 4651, 2020.
5. Zongjun Liu#, Tuo Li, Fang Han, You Wang,* Yang Gan,* Junhui Shi, Tianran Wang, Muhammad Luqman Akhtar, and Yu Li*.A Cascade-Reaction Enabled Synergistic Cancer Starvation/ROS-mediated /chemotherapy with Enzyme Modified Fe-based MOF. Biomater Sci,7(9): 3683-3692, 2019.
6. Chunbin Zhang, Fang Han, Ming Shi, Haoxiu Sun, Yiqun Li, Yanpeng Ci, Yuanfei Yao, Peng Dou, Muhammad luqman Akhtar, Huan Nie, Jie He, Li Y*. MARVELD1 interacting with catalase regulates reactive oxygen species metabolism and mediates the sensitivity to chemotherapeutic drugs in epithelial tumors of the reproductive system. Mol Carcinog, 08;58(8):1410-1426, 2019.
7. Xin Lu, Xiaohan Zhang, Yongjian Zhang, Kun Zhang, Chao Zhan, Xiuyun Shi, Yiqun Li, Jianxiang Zhao, Yunfan Bai, Yu Wang, Huan Nie*, Yu Li*. Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2. Mol Carcinog, 58(5):749-759. doi: 10.1002/mc.22967.2019.
8. Yanpeng Ci, Xiaoning Li, Maorong Chen, Jiateng Zhong, Brian J. North, Hiroyuki Inuzuka, Xi He, Yu Li* & Jianping Guo* & Xiangpeng Dai*. SCF E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation. Protein Cell,9(10):879-889, 2018.
9. Weizhe Liu, Fang Han, Shuai Qu, Yuanfei Yao, Jianxiang Zhao, Muhammad Luqman Akhtar, Yanpeng Ci, Hao Zhang, Hongfei Li, Yufang Zhao, Lei Yue, Yao Zhang, Changlin Wang*&Yu Li*. MARVELD1 depletion leads to dysfunction of motor and cognition via regulating glia-dependent neuronal migration during brain development. Cell Death & Disease, 9: 999, 2018.
10. Chen Y, Zhang H, Han F, Yue L, Qiao C, Zhang Y, Dou P, Liu W, Li Y*. The depletion of MARVELD1 leads to murine placenta accreta via integrin β4-dependent trophoblast cell invasion. J Cell Physiol, 233(3): 2257-2269, 2018.
11. Yao Y, Shi M, Liu S, Li Y, Guo K, Ci Y, Liu W, Li Y*. MARVELD1 modulates cell surface morphology and suppresses epithelial-mesenchymal transition in non-small cell lung cancer. Mol Carcinog.55(11):1714-1727. doi: 10.1002/mc.22421. 2016.
主要发明专利：
1. 人源调控细胞死亡的C1ORF109重组蛋白及其制备方法与应用。授权编号：2018111449544。发明人排序：第一位。
2. 一种胰腺导管腺癌标志物及其筛选方法。授权编号：2018110521959。发明人排序：第二位。
教师个人主页链接
http://homepage.hit.edu.cn/liyu
